Your Embryos Are Good, But They're Not Implanting. Here's Why.

MTHFR is an enzyme that sits at the center of your methylation cycle. This cycle provides the methyl groups your cells use to build and repair DNA, regulate gene expression, and manage neurotransmitters and hormones. In pregnancy, methylation is especially critical. Your embryo’s cells are dividing rapidly. Neural tubes are closing. Epigenetic patterns are being laid down. All of this requires methylation.

The C677T variant of MTHFR, carried by roughly 40% of people with European ancestry, reduces the enzyme’s efficiency by 40 to 70 percent. That means your cells convert folate into methylfolate at a slower rate. You can eat a perfect diet rich in leafy greens and still be functionally depleted of usable methyl groups at the cellular level.

For implantation, this matters acutely. Your endometrial cells are preparing to receive an embryo. Your embryo is undergoing the most rapid cell division of its entire life. Both processes demand active methylation. When MTHFR is impaired, endometrial receptivity may be compromised. Embryos that would implant successfully in a woman with normal MTHFR may fail to implant in you.

FSHR is the receptor on your ovarian follicle cells that responds to FSH, the hormone your pituitary releases to stimulate egg growth. Think of it as a lock. FSH is the key. The N680S variant is a subtle change in the shape of that lock. It does not break the lock. It changes how efficiently the key turns it.

The S/S variant, present in roughly 10 to 15 percent of women, is associated with a slower or weaker response to FSH stimulation. Women with this variant often produce fewer mature eggs during a standard IVF protocol. They may require higher doses of FSH or longer stimulation to achieve the same number of eggs as women with the N/N variant. This is not a sign of low ovarian reserve. It is a sign of poor dose sensitivity.

On your IVF cycle, if you have the S/S variant, a standard protocol may leave you underresponsive. You inject the same dose everyone else injects. Your follicles grow slower. You may need to extend your stimulation. You may produce fewer eggs than your age and AMH suggest you should. Your doctor may wrongly conclude you have low reserve. You actually have an FSH receptor that requires a more assertive approach.

ESR1 encodes the estrogen receptor alpha, the protein that sits on endometrial cells and listens for estrogen signals. When estrogen binds to this receptor, it tells your endometrium to grow, thicken, and prepare for implantation. But not all estrogen receptors are equally sensitive. Variants in ESR1, particularly the PvuII and XbaI polymorphisms, subtly alter how efficiently the receptor responds to estrogen.

Roughly 40 percent of women carry at least one of these variants. In itself, this is not a problem. But during the luteal phase, when progesterone rises and estrogen should be declining, women with certain ESR1 variants may have altered endometrial sensitivity to estrogen signaling. This can impair the final maturation of the endometrium that allows implantation. Even with perfect hormone levels, your endometrium may not be receiving the right message from estrogen at the right time.

For implantation, timing is everything. Your embryo arrives at the uterus five to six days after fertilization. Your endometrium has a window of about 12 hours when it is optimally receptive. If your endometrial cells are not properly sensitized to estrogen signaling because of your ESR1 variant, that window may close before your embryo is ready to knock. Your embryo may be perfect. Your endometrium may be thick and healthy. But the two are out of sync.

COMT is an enzyme that degrades catecholamines (dopamine, norepinephrine, epinephrine) and estrogen metabolites. When COMT works efficiently, it keeps estrogen levels balanced. When COMT is slow, estrogen accumulates. The Val158Met variant is common. The Met allele produces a slower version of COMT. Roughly 25 percent of people with European ancestry are homozygous for the slow version.

Slow COMT means estrogen lingers in your bloodstream longer than it should. In the follicular phase, this might be fine. But as you approach ovulation and enter the luteal phase, elevated estrogen from slow clearance can tip your system toward a pro-inflammatory state. This elevated estrogen exposure is associated with endometriosis, PCOS, and,critically for implantation,reduced endometrial receptivity. Your estrogen levels on a blood test may look normal, but your tissue estrogen exposure is elevated, and your endometrium is irritated.

On your IVF cycle, this matters in a specific way. You inject exogenous estrogen to prepare your endometrium. If your COMT is slow, that estrogen is clearing slowly. You may end up with higher estrogen levels than intended. This can trigger inflammation in your endometrium and paradoxically reduce implantation.

VDR encodes the vitamin D receptor, a protein that binds activated vitamin D and tells your cells what to do with it. Vitamin D is not just about bone health. It is a key regulator of immune tolerance, inflammatory response, and endometrial health. Your endometrium needs vitamin D signaling to suppress excessive inflammation and prepare for implantation. Your immune system needs vitamin D to distinguish between helpful inflammation (like fighting an infection) and harmful inflammation (like attacking an implanting embryo).

VDR has several polymorphisms. The most studied are FokI, BsmI, ApaI, and TaqI. These variants do not change the amount of VDR your cells make. They change how efficiently the VDR protein functions. Certain combinations are associated with vitamin D insufficiency at higher serum levels, impaired immune tolerance, and increased risk of autoimmune activation against pregnancy-related antigens. You can have a vitamin D level of 40 ng/mL on a blood test and still have poor VDR responsiveness because of your genetic variant.

For implantation, this creates a specific vulnerability. Your embryo is genetically foreign to your immune system. It shares DNA from the father. Your immune system must tolerate this genetic outsider. VDR-mediated vitamin D signaling is one of the key pathways that teaches your immune system to allow implantation rather than reject it.

FMR1 stands for Fragile X mental retardation 1. It is famous for causing Fragile X syndrome when fully mutated. But most people have heard of FMR1 only in that context. Far fewer know that FMR1 premutations are a major cause of premature ovarian insufficiency in women. A premutation is a CGG repeat expansion in FMR1 that falls between 55 and 200 repeats. A normal FMR1 has fewer than 44 repeats.

Roughly 1 in 250 women carry an FMR1 premutation. These women often have normal fertility in their twenties and thirties. But between ages 35 and 45, their ovaries deplete rapidly. FSH rises. AMH falls. Egg quality declines. This is not because they have low ovarian reserve from the start. It is because the FMR1 premutation is slowly poisoning their follicle cells. The mechanism is not fully understood, but it involves impaired cellular stress responses and increased oxidative damage in oocytes. If you carry an FMR1 premutation and you are over 35, your window for egg banking or fresh cycles may be much narrower than your age alone suggests.

For implantation, FMR1 premutations create a dual problem. First, you have fewer eggs. Second, the eggs you do have are more likely to have developmental abnormalities that prevent implantation. You may see more failed transfers not because your endometrium is unreceptive, but because your embryos are chromosomally compromised or have epigenetic damage.